Porterhouse Medical Group is delighted to welcome David Eatwell, who joins the team at Porterhouse Insights as Director.

David, an experienced and innovative pharma insight professional, will bolster the expertise and capabilities in insight generation and strategy development.

David is joining from Cello Health Insight, having previously worked within Consulting at McCann Health (formerly Double Helix) since 2006, where he headed up the Quantitative Centre of Excellence for the global team.
He holds a BSc Hons (ARCS) degree in Chemistry from Imperial College London, as well as a degree in Management from the Imperial College Business School in London. Earlier in his career, he worked at Novartis Pharmaceuticals in the company headquarters in Switzerland within the combinatorial lead synthesis chemistry research team before beginning his 14+ years career in strategic pharmaceutical insights.

David has a background in both qualitative and quantitative research methodologies, across a very broad spectrum of therapy areas and business needs. He specialises in advanced quantitative methodologies and novel ways to approach research and insight generation.

Managing Director, Fabrice Allum says: “I am delighted that someone of David’s calibre is joining the Porterhouse Insights team. Following a tremendous year, where we have broken new ground in terms of clients and methodologies and become part of imc group supported by WPE, we are looking to expand the reach of our smarter Insights solutions. David, with his innovative approaches and problem-solving mindset will help us deliver these to our clients and support their business decisions through these challenging times.”